Cerebral Embolic Protection Devices in Transcatheter Aortic Valve Implantation: Meta‐Analysis With Trial Sequential Analysis
Journal of the American Heart Association · 2025-04 · 14 (7)
DOI: 10.1161/jaha.124.038869 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of the American Heart Association, 2025-04. Verfasst von Nav Warraich und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiac Surgery, Department of Cardiothoracic Surgery University of Pittsburgh Pittsburgh PA USA. Hauptthemen laut MEDLINE: Embolic Protection Devices, Transcatheter Aortic Valve Replacement, Intracranial Embolism, Aortic Valve Stenosis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
We aimed to reevaluate randomized controlled trial data on outcomes of cerebral embolic protection device use during transcatheter aortic valve implantation. A conventional meta‐analysis followed by trial sequential analysis was conducted to evaluate the strength of the current evidence. Methods and Results Databases were searched for randomized controlled trials. Primary outcomes included all stroke, disabling stroke, and all‐cause mortality. Conventional study‐level meta‐analysis was performed using random‐effects modeling. Trial sequential analysis was conducted to generate adjusted significance boundaries, futility boundaries, and the required information size considering a type I error of 5% and a power of 90%. Seven trials were included with a total of 4031 patients, of whom 2171 were treated with a device and 1860 were not. Conventional meta‐analysis showed no significant difference in all stroke (relative risk [RR], 0.85 [95% CI, 0.61–1.18]; P =0.339) and disabling stroke (RR, 0.59 [95% CI, 0.30–1.13]; P =0.113) with device use. The trial sequential analysis determined an absence of evidence for all stroke (required information size of 71 650 [5.6%]) and disabling stroke (required information size of 337 256 [1.2%]). Conventional meta‐analysis determined no significant difference in all‐cause mortality (RR, 1.03 [95% CI, 0.49–2.17]; P =0.928) with device use. The trial sequential analysis determined that the futility boundary was reached (required information size of 5772 [69.3%]).
Conclusions
There are insufficient randomized controlled trial data on cerebral embolic protection device use to provide conclusive meta‐analytic findings for stroke outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiac Surgery, Department of Cardiothoracic Surgery University of Pittsburgh Pittsburgh PA USA.
- UPMC Heart and Vascular Institute, University of Pittsburgh Medical Center Pittsburgh PA USA.
- Division of Cardiac Surgery Massachusetts General Hospital, Harvard Medical School Boston MA USA.
- KU Leuven Leuven Belgium.
- Division of Cardiology, Massachusetts General Hospital Harvard Medical School Boston MA USA.
ORCID-Profile: Nav Warraich, Michel Pompeu Sá, Xander Jacquemyn, Toshiki Kuno, Derek Serna-Gallegos, Ibrahim Sultan
Zitieren
APA
Warraich, N., Sá, M. P., Jacquemyn, X., Kuno, T., Serna-Gallegos, D., & Sultan, I. (2025). Cerebral Embolic Protection Devices in Transcatheter Aortic Valve Implantation: Meta‐Analysis With Trial Sequential Analysis. Journal of the American Heart Association, 14(7). https://doi.org/10.1161/jaha.124.038869
Vancouver
Warraich N, Sá MP, Jacquemyn X, Kuno T, Serna-Gallegos D, Sultan I. Cerebral Embolic Protection Devices in Transcatheter Aortic Valve Implantation: Meta‐Analysis With Trial Sequential Analysis. Journal of the American Heart Association. 2025;14(7). doi:10.1161/jaha.124.038869
BibTeX
@article{Warraich2025,
author = {Warraich, Nav and Sá, Michel Pompeu and Jacquemyn, Xander and Kuno, Toshiki and Serna-Gallegos, Derek and Sultan, Ibrahim},
title = {Cerebral Embolic Protection Devices in Transcatheter Aortic Valve Implantation: Meta‐Analysis With Trial Sequential Analysis},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {7},
doi = {10.1161/jaha.124.038869}
}
EUVIMED